Kimberly-Clark (KMB) 10-Q 21 Oct 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 14, 2014
Document And Entity Information	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'
Entity Registrant Name	'KIMBERLY CLARK CORP	'
Entity Central Index Key	'0000055785	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	372,455,181

Consolidated_Income_Statement_

Consolidated Income Statement Consolidated Income Statement (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net Sales	$5,442	$5,262	$16,063	$15,847
Cost of products sold	3,541	3,457	10,528	10,420
Gross Profit	1,901	1,805	5,535	5,427
Marketing, research and general expenses	1,011	990	3,014	3,029
Other (income) and expense, net	-17	8	27	12
Operating Profit	907	807	2,494	2,386
Interest income	5	6	13	16
Interest expense	71	73	214	211
Income Before Income Taxes and Equity Interests	841	740	2,293	2,191
Provision for income taxes	290	224	749	685
Income Before Equity Interests	551	516	1,544	1,506
Share of net income of equity companies	31	49	114	157
Net Income	582	565	1,658	1,663
Net income attributable to noncontrolling interests	20	19	49	60
Net Income Attributable to Kimberly-Clark Corporation	$562	$546	$1,609	$1,603
Basic	$1.51	$1.43	$4.28	$4.16
Diluted	$1.50	$1.42	$4.25	$4.13
Cash Dividends Declared	$0.84	$0.81	$2.52	$2.43

Consolidated_Statement_Of_Comp

Consolidated Statement Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net Income	$582	$565	$1,658	$1,663
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'
Unrealized currency translation adjustments	-529	204	-366	-387
Employee postretirement benefits	46	-5	72	84
Other	30	-19	19	9
Total Other Comprehensive Income (Loss), Net of Tax	-453	180	-275	-294
Comprehensive Income	129	745	1,383	1,369
Comprehensive income attributable to noncontrolling interests	-8	-32	-45	-59
Comprehensive Income Attributable to Kimberly-Clark Corporation	$121	$713	$1,338	$1,310

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$1,431	$1,054
Accounts receivable, net	2,542	2,545
Inventories	2,281	2,233
Other current assets	667	718
Total Current Assets	6,921	6,550
Property, Plant and Equipment, Net	7,692	7,948
Investments in Equity Companies	335	382
Goodwill	3,129	3,181
Other Intangible Assets	215	243
Other Assets	584	615
TOTAL ASSETS	18,876	18,919
Current Liabilities	'	'
Debt payable within one year	773	375
Redeemable preferred securities of subsidiary	506	506
Trade accounts payable	2,597	2,598
Accrued expenses	2,071	2,060
Dividends payable	313	309
Total Current Liabilities	6,260	5,848
Long-Term Debt	5,633	5,386
Noncurrent Employee Benefits	1,090	1,312
Deferred Income Taxes	902	817
Other Liabilities	371	344
Redeemable Preferred and Common Securities of Subsidiaries	72	72
Stockholders' Equity	'	'
Kimberly-Clark Corporation	4,265	4,856
Noncontrolling Interests	283	284
Noncontrolling Interests	4,548	5,140
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$18,876	$18,919

Consolidated_Cash_Flow_Stateme

Consolidated Cash Flow Statement (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating Activities	'	'
Net Income	$1,658	$1,663
Depreciation and amortization	655	641
Asset impairments	42	42
Stock-based compensation	51	73
Deferred income taxes	57	128
Net (gains) losses on asset dispositions	-11	0
Equity companies' earnings in excess of dividends paid	-27	-75
(Increase) decrease in operating working capital	-63	-259
Postretirement benefits	-119	-135
Other	12	17
Cash Provided by Operations	2,255	2,095
Investing Activities	'	'
Capital spending	-730	-697
Acquisitions of businesses	0	-32
Proceeds from dispositions of property	36	113
Proceeds from sales of investments	96	16
Investments in time deposits	-123	-46
Maturities of time deposits	191	66
Other	5	-10
Cash Used for Investing	-525	-590
Financing Activities	'	'
Cash dividends paid	-942	-913
Change in short-term borrowings	153	22
Debt proceeds	621	889
Debt repayments	-109	-542
Cash paid on redeemable preferred securities of subsidiaries	-22	-21
Proceeds from exercise of stock options	98	164
Acquisitions of common stock for the treasury	-1,122	-959
Other	0	7
Cash Used for Financing	-1,323	-1,353
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-30	-79
Increase (Decrease) in Cash and Cash Equivalents	377	73
Cash and Cash Equivalents - Beginning of Year	1,054	1,106
Cash and Cash Equivalents - End of Period	$1,431	$1,179

Accounting_Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form  10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.
	For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form  10-K for the year ended December 31, 2013. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. For 2014, we have completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter as the measurement date and have determined that goodwill is not impaired. The fair value for all reporting units was in excess of the book value.
	Highly Inflationary Accounting for Venezuelan Operations
	We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after-tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to this devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations.
	During March 2013, the Venezuelan government announced a complementary currency exchange system, SICAD. Participation in SICAD is controlled by the Venezuelan government. SICAD is intended to function as an auction system, allowing entities in specific sectors to bid for U.S. dollars to be used for specified import transactions. In February 2014, the president of Venezuela announced that another exchange system (referred to as SICAD 2) would be initiated. Initial exchanges under SICAD 2 began on March 24, 2014.
	We measure results in Venezuela at the rate in which we transact our business. Since March 2013, exchange transactions have taken place through letters of credit which resulted in an effective exchange rate of 6.3 bolivars per U.S. dollar and through approved transactions using the regulated currency exchange system, which were also at a 6.3 exchange rate. To date, we have not gained access to U.S. dollars in Venezuela through either SICAD or SICAD 2 auctions. Whether we will be able to access either SICAD system in the foreseeable future and what volume of currency exchange will transact through these alternative mechanisms is unclear. Accordingly, we continued to measure K-C Venezuela operations at the rate of 6.3 bolivars per U.S. dollar through September 30, 2014.
	Through September 30, 2014 we continued to manufacture products in Venezuela as well as import finished goods under approved letters of credit. However, recent government approvals to import raw materials under letters of credit are not at a level sufficient to sustain all of our manufacturing capabilities in country. Unless we are able to obtain further approvals to import raw materials through approved letters of credit or through the official government exchange system, we may be forced to curtail some or all of our local manufacturing until such approvals to import additional raw materials are forthcoming. We continue to seek approval for additional imports, as well as monitor the financial policies and practices of the Venezuelan government to assess the impact on our US GAAP accounting and reporting for our operations in that country.
	At September 30, 2014, K-C Venezuela had a bolivar-denominated net monetary asset position (primarily cash) of $435, and our net investment in K-C Venezuela was $572, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented less than 3 percent of consolidated net sales in 2014 and approximately 2 percent in 2013.
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance.  The standard is effective for public entities for annual and interim periods beginning after December 15, 2016.  Early adoption is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The effects of this standard on our financial position, results of operations and cash flows are not yet known.

Spinoff_of_Health_Care_Busines

Spin-off of Health Care Business	9 Months Ended
	Sep. 30, 2014
Restructuring Cost and Reserve	'
Restructuring and Related Activities Disclosure	'
	2014 Organization Restructuring
	In October 2014, we initiated a restructuring plan in order to improve organization efficiency and offset the impact of stranded overhead costs resulting from the spin-off of our health care business. The restructuring is intended to improve our underlying profitability and increase our flexibility to invest in targeted growth initiatives, brand building and other capabilities critical to delivering future growth.
	The restructuring is expected to be completed by the end of 2016, with total costs anticipated to be $130 to $160 after tax ($190 to $230 pre-tax). Cash costs are projected to be approximately 80 percent of the total charges. Workforce reductions are expected to be in the range of 1,100 to 1,300 and primarily impact salaried employees. We expect that $85 to $105 of the after-tax charges ($125 to $150 pre-tax) will occur in the fourth quarter of 2014. The restructuring is expected to impact all of our business segments and our organizations in all major geographies.
Spinoff [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Activities Disclosure	'
	pin-Off of Health Care Business and Related Costs
	In November 2013, we announced that our Board of Directors authorized management to pursue a potential tax-free spin-off of our health care business. The spin-off will create a stand-alone, publicly traded health care company with approximately $1.7 billion in annual net sales, focused on the sale of surgical and infection prevention products for the operating room and other medical supplies, and medical devices focused on pain management, respiratory and digestive health.
	A Form 10 registration statement was filed in May 2014 with the Securities and Exchange Commission (the "SEC") to register our health care business as an independent stand-alone public company named Halyard Health, Inc. (“Halyard”). In September 2014, our Board of Directors authorized its executive committee (“Executive Committee”) to approve the final terms and conditions of the distribution.  On October 6, 2014, the Executive Committee approved the distribution of all of the issued and outstanding shares of Halyard common stock on the basis of one share of Halyard common stock for every eight shares of Kimberly-Clark common stock held as of the close of business on October 23, 2014, the record date for the distribution. The Form 10 registration statement, as amended, was deemed effective by the SEC on October 17, 2014. We expect that the spin-off will be completed at the end of the day on October 31, 2014, subject to market, regulatory and other conditions.
	Halyard will fund a cash distribution to us equal to the estimated amount of all of Halyard's available cash on the distribution date in excess of the minimum amount to be retained by Halyard. Such minimum amount will be equal to $40 plus the estimated net amount of certain intercompany assets and liabilities on the distribution date that are to be retained by us plus approximately $1 associated with certain retention bonus obligations to be transferred to Halyard. The amount of funds resulting from the intercompany settlements will be determined on or about the date of the distribution, although the exact amount will depend on the amount of the cash distribution and the intercompany transactions.  We expect to use the proceeds of this cash distribution to make open-market repurchases of our shares of common stock.
	After the spin-off, the divested health care business will be presented as discontinued operations, which will exclude overhead costs previously allocated to health care that will remain part of Kimberly-Clark after the spin-off, on our Consolidated Income Statement for all periods presented. The health care business' balance sheet, other comprehensive income and cash flows will be included within our Consolidated Balance Sheet, Consolidated Statement of Stockholders' Equity, Consolidated Statement of Comprehensive Income and Consolidated Cash Flow Statement through October 31, 2014.
	In June 2014, we decided to exit one of our health care glove manufacturing facilities in Thailand and outsource the related production in order to improve our ongoing cost and competitive position.  The plan is expected to result in charges of approximately $70 ($50 after tax).  Charges recognized in cost of products sold during the three and nine months ended September 30, 2014 were $5 and $54, consisting primarily of an asset impairment charge of $42. In addition, during the three and nine months ended September 30, 2014, $30 and $56 were recorded, respectively, in marketing, research and general expenses, and $5 was recorded in cost of products sold, for transaction and related costs associated with the potential spin-off of our health care business.  Total charges during the three and nine months ended September 30, 2014 for these matters were $40 and $115 ($41 and $94 after tax), respectively.

2014_Organization_Restructurin

2014 Organization Restructuring	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring and Related Activities Disclosure	'
	2014 Organization Restructuring
	In October 2014, we initiated a restructuring plan in order to improve organization efficiency and offset the impact of stranded overhead costs resulting from the spin-off of our health care business. The restructuring is intended to improve our underlying profitability and increase our flexibility to invest in targeted growth initiatives, brand building and other capabilities critical to delivering future growth.
	The restructuring is expected to be completed by the end of 2016, with total costs anticipated to be $130 to $160 after tax ($190 to $230 pre-tax). Cash costs are projected to be approximately 80 percent of the total charges. Workforce reductions are expected to be in the range of 1,100 to 1,300 and primarily impact salaried employees. We expect that $85 to $105 of the after-tax charges ($125 to $150 pre-tax) will occur in the fourth quarter of 2014. The restructuring is expected to impact all of our business segments and our organizations in all major geographies.

European_Strategic_Changes

European Strategic Changes	9 Months Ended
	Sep. 30, 2014
Restructuring Cost and Reserve	'
European Strategic Changes	'
	2014 Organization Restructuring
	In October 2014, we initiated a restructuring plan in order to improve organization efficiency and offset the impact of stranded overhead costs resulting from the spin-off of our health care business. The restructuring is intended to improve our underlying profitability and increase our flexibility to invest in targeted growth initiatives, brand building and other capabilities critical to delivering future growth.
	The restructuring is expected to be completed by the end of 2016, with total costs anticipated to be $130 to $160 after tax ($190 to $230 pre-tax). Cash costs are projected to be approximately 80 percent of the total charges. Workforce reductions are expected to be in the range of 1,100 to 1,300 and primarily impact salaried employees. We expect that $85 to $105 of the after-tax charges ($125 to $150 pre-tax) will occur in the fourth quarter of 2014. The restructuring is expected to impact all of our business segments and our organizations in all major geographies.
European Strategic Changes [Member]	'
Restructuring Cost and Reserve	'
European Strategic Changes	'
	European Strategic Changes
	In 2012, we initiated strategic changes related to our Western and Central European consumer and professional businesses to focus our resources and investments on stronger market positions and growth opportunities. We have exited the diaper category in that region, with the exception of the Italian market, and divested or exited some lower-margin businesses, mostly in consumer tissue, in certain markets. The changes primarily affect our consumer businesses, with a modest impact on K-C Professional ("KCP"). The restructuring actions commenced in 2012 and are expected to be completed by December 31, 2014.
	Restructuring actions related to the strategic changes involved the sale or closure of five of our European manufacturing facilities and the streamlining of our administrative organization.
	Total charges related to the European strategic changes during the three months ended September 30, 2014 and 2013 were $1 and $14 ($3 and $10 after tax), respectively. Total charges related to these actions during the nine months ended September 30, 2014 and 2013 were $13 and $67 ($12 and $52 after tax), respectively.
	Through September 30, 2014, cumulative pre-tax charges for the strategic changes were $393 ($320 after tax), including cumulative pre-tax cash charges of $215.
	The following summarizes the cash charges recorded and reconciles these charges to accrued expenses:
		2014			2013
	Accrued expenses - January 1	$	37		$	133
	Charges for workforce reductions and other exit costs	12			53
	Cash payments	(32		)	(132		)
	Currency and other	(2		)	(9		)
	Accrued expenses - September 30	$	15		$	45

Fair_Value_Information

Fair Value Information	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Information	'
	Fair Value Information
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	During the nine months ended September 30, 2014 and for the full year 2013, there were no significant transfers among level 1, 2, or 3 fair value determinations.
	Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements.
		September 30,				Fair Value Measurements
		2014				Level 1				Level 2				Level 3
	Assets
	Company-owned life insurance (“COLI”)	$	57			$	—			$	57			$	—
	Available-for-sale securities	24				24				—				—
	Derivatives	44				—				44				—
	Total	$	125			$	24			$	101			$	—
	Liabilities
	Derivatives	$	105			$	—			$	105			$	—
		December 31,				Fair Value Measurements
		2013				Level 1				Level 2				Level 3
	Assets
	COLI	$	55			$	—			$	55			$	—
	Available-for-sale securities	22				22				—				—
	Derivatives	62				—				62				—
	Total	$	139			$	22			$	117			$	—
	Liabilities
	Derivatives	$	49			$	—			$	49			$	—
	The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in other assets. Available-for-sale securities are included in other assets. See Note 9 for information on the classification of derivatives in the Consolidated Balance Sheet.
	Level 1 Fair Values - The fair values of certain available-for-sale securities are based on quoted market prices in active markets for identical assets.
	Level 2 Fair Values - The fair value of the COLI policies is derived from investments in a mix of money market, fixed income and equity funds managed by unrelated fund managers. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and NYMEX price quotations, respectively. The fair value of hedging instruments used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Additional information on our use of derivative instruments is contained in Note 9.
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value Hierarchy Level		Carrying Amount				Estimated Fair Value				Carrying Amount				Estimated Fair Value
				September 30, 2014								December 31, 2013
	Assets
	Cash and cash equivalents(a)	1		$	1,431			$	1,431			$	1,054			$	1,054
	Time deposits(b)	1		154				154				222				222
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(c)	2		213				213				63				63
	Long-term debt(d)	2		6,193				6,856				5,698				6,271
	Redeemable preferred securities of subsidiaries(e)	3		532				535				532				552
	Redeemable common securities of subsidiary(f)	3		46				46				46				46
	(a)	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(d)	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(e)	Redeemable preferred securities of subsidiaries are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates.
	(f)	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi

Employee Postretirement Benefits	9 Months Ended
	Sep. 30, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Employee Postretirement Benefits	'
	Employee Postretirement Benefits
	The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans:
		Pension Benefits						Other Benefits
		Three Months Ended September 30
		2014			2013			2014		2013
	Service cost	$	12		$	13		$	3	$	4
	Interest cost	70			63			9		9
	Expected return on plan assets	(83		)	(82		)	—		—
	Recognized net actuarial loss	25			28			—		2
	Curtailment	—			(1		)	—		—
	Other	1			2			—		—
	Net periodic benefit cost	$	25		$	23		$	12	$	15
		Pension Benefits						Other Benefits
		Nine Months Ended September 30
		2014			2013			2014		2013
	Service cost	$	36		$	40		$	9	$	12
	Interest cost	209			191			27		25
	Expected return on plan assets	(249		)	(246		)	—		—
	Recognized net actuarial loss	75			91			—		2
	Curtailment	—			(30		)	—		—
	Other	6			(1		)	—		—
	Net periodic benefit cost	$	77		$	45		$	36	$	39
	For the nine months ended September 30, 2014 and 2013, we made cash contributions of $180 and $175, respectively, to our pension trusts. We expect to contribute approximately $200 to our defined benefit pension plans for the full year 2014.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share ("EPS")
	There are no adjustments required to be made to net income for purposes of computing EPS. A reconciliation of the average number of common shares outstanding used in the basic and diluted EPS computations follows:
		Three Months Ended		Nine Months Ended
		30-Sep		30-Sep
	(Millions of shares)	2014	2013	2014	2013
	Basic	373.3	382.8	376	384.9
	Dilutive effect of stock options	1.1	1.4	1.2	1.6
	Dilutive effect of restricted share and restricted share unit awards	1.5	1.6	1.6	1.5
	Diluted	375.9	385.8	378.8	388
	There were no significant outstanding stock-based awards excluded from the computation of diluted EPS during the three and nine month periods ended September 30, 2014 and 2013.
	The number of common shares outstanding as of September 30, 2014 and 2013 was 372.5 million and 382.1 million, respectively.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	Set forth below is a reconciliation for the nine months ended September 30, 2014 of the carrying amount of total stockholders' equity from the beginning of the period to the end of the period.
			Stockholders' Equity Attributable to
			The Corporation			Noncontrolling Interests
	Balance at December 31, 2013		$	4,856		$	284
	Net Income		1,609			25
	Other comprehensive income, net of tax
	Unrealized translation		(362		)	(3		)
	Employee postretirement benefits		72			—
	Other		19			—
	Stock-based awards exercised or vested		99			—
	Recognition of stock-based compensation		51			—
	Income tax benefits on stock-based compensation		30			—
	Shares repurchased		(1,162		)	—
	Dividends declared		(946		)	(26		)
	Other		(1		)	3
	Balance at September 30, 2014		$	4,265		$	283
	During the nine months ended September 30, 2014, we repurchased 10.3 million shares at a total cost of $1.1 billion.
	Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in accumulated other comprehensive income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation is recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation.
	Also included in unrealized translation are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.
	The change in net unrealized currency translation for the nine months ended September 30, 2014 was primarily due to the strengthening of the U.S. dollar against the Euro, Russian ruble and Australian dollar, as well as most other currencies.
	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
			Unrealized Translation			Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2012		$	(26	)	$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income (loss) before reclassifications		(386		)	57				1				17
	(Income) loss reclassified from AOCI		—			28			(a)	(2		)	(a)	(8		)
	Net current period other comprehensive income (loss)		(386		)	85				(1		)		9
	Balance as of September 30, 2013		$	(412	)	$	(1,843	)		$	(54	)		$	(43	)
	Balance as of December 31, 2013		$	(525	)	$	(1,668	)		$	(15	)		$	(34	)
	Other comprehensive income (loss) before reclassifications		(362		)	(2		)		24				17
	(Income) loss reclassified from AOCI		—			49			(a)	1			(a)	2
	Net current period other comprehensive income (loss)		(362		)	47				25				19
	Balance as of September 30, 2014		$	(887	)	$	(1,621	)		$	10			$	(15	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 6).

Objectives_And_Strategies_For_

Objectives And Strategies For Using Derivatives	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Objectives And Strategies For Using Derivatives	'
	Objectives and Strategies for Using Derivatives
	As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments.
	Interest rate risk is managed using a portfolio of variable- and fixed-rate debt composed of short- and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable- and fixed-rate debt and are designated and qualify as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, using forward-starting swaps, and these contracts are designated as cash flow hedges.
	We use derivative instruments, such as forward swap contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months.
	Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowing. Translation exposure, which results from changes in translation rates between functional currencies and the U.S. dollar, generally is not hedged. However, consistent with other years, a portion of our net investment in our Mexican affiliate has been hedged. At September 30, 2014, we had in place net investment hedges of $74 for a portion of our investment in our Mexican affiliate.
	Set forth below is a summary of the total designated and undesignated fair values of our derivative instruments:
		Assets				Liabilities
		September 30,		December 31,		September 30,		December 31,
		2014		2013		2014		2013
	Foreign currency exchange contracts	$	38	$	34	$	104	$	49
	Interest rate contracts	4		22		1		—
	Commodity price contracts	2		6		—		—
	Total	$	44	$	62	$	105	$	49
	The derivative assets are included in the Consolidated Balance Sheet in other current assets and other assets, as appropriate. The derivative liabilities are included in the Consolidated Balance Sheet in accrued expenses and other liabilities, as appropriate.
	Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in current earnings. The offset to the change in fair values of the related hedged items also is recorded in current earnings. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to interest expense over the life of the related debt. At September 30, 2014, the aggregate notional values of outstanding interest rate contracts designated as fair value hedges were $250. Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2014 and 2013. For the three and nine month periods ended September 30, 2014 and 2013, gains or losses recognized in interest expense for interest rate swaps were not significant. For the nine month periods ended September 30, 2014 and 2013, no gain or loss was recognized in earnings as a result of a hedged firm commitment no longer qualifying as a fair value hedge.
	For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. As of September 30, 2014, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of 2014 and future periods. As of September 30, 2014, the aggregate notional values of outstanding foreign exchange and interest rate derivative contracts designated as cash flow hedges were $900 and $200, respectively. Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2014 and 2013. For the nine months ended September 30, 2014 and 2013, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2014, amounts to be reclassified from AOCI during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at September 30, 2014 is July 2017.
	Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in other (income) and expense, net. Losses of $130 and gains of $77 were recorded in the three month periods ended September 30, 2014 and 2013, respectively. Losses of $77 and $65 were recorded in the nine month periods ended September 30, 2014 and 2013, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2014, the notional amount of these undesignated derivative instruments was $2.4 billion.

Description_Of_Business_Segmen

Description Of Business Segments	9 Months Ended
	Sep. 30, 2014
Description of Business Segments	'
Description Of Business Segments	'
	Description of Business Segments
	We are organized into operating segments based on product groupings. These operating segments have been aggregated into four reportable global business segments: Personal Care, Consumer Tissue, KCP and Health Care. The reportable segments were determined in accordance with how our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes other (income) and expense, net and income and expense not associated with the business segments. Costs associated with the spin-off of the health care business and related matters are included in Corporate & Other.
	The principal sources of revenue in each global business segment are described below:
	•	Personal Care brands offer parents a trusted partner in caring for their families and deliver confidence, protection and discretion to adults through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, Poise and other brand names.
	•	Consumer Tissue offers a wide variety of innovative solutions and trusted brands that touch and improve people's lives every day.  Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve and other brand names.
	•	K-C Professional helps transform workplaces for employees and patrons, making them healthier, safer and more productive, through a range of solutions and supporting products such as apparel, wipers, soaps, sanitizers, tissue and towels.  Key brands in this segment include Kleenex, Scott, WypAll, Kimtech and Jackson Safety.
	•	Health Care provides essentials that help restore patients to better health and improve the quality of patients' lives. This segment offers surgical and infection prevention products for the operating room, and a portfolio of innovative medical devices focused on pain management, respiratory and digestive health. This business is a global leader in education to prevent healthcare-associated infections. Products are sold primarily under the Kimberly-Clark and ON-Q brand names.
	The following schedules present information concerning consolidated operations by business segment:
			Three Months Ended September 30								Nine Months Ended
											30-Sep
			2014			2013			Change		2014			2013			Change
	NET SALES
	Personal Care		$	2,475		$	2,383		3.9	%	$	7,299		$	7,170		1.8	%
	Consumer Tissue		1,697			1,626			4.4	%	5,024			4,969			1.1	%
	K-C Professional		873			843			3.6	%	2,531			2,477			2.2	%
	Health Care		392			403			-2.7	%	1,186			1,201			-1.2	%
	Corporate & Other		5			7			N.M.		23			30			N.M.
	TOTAL NET SALES		$	5,442		$	5,262		3.4	%	$	16,063		$	15,847		1.4	%
	OPERATING PROFIT
	Personal Care		$	483		$	427		13.1	%	$	1,393		$	1,300		7.2	%
	Consumer Tissue		285			233			22.3	%	782			713			9.7	%
	K-C Professional		165			155			6.5	%	455			459			-0.9	%
	Health Care		52			70			-25.7	%	187			168			11.3	%
	Corporate & Other(a)		(95		)	(70		)	N.M.		(296		)	(242		)	N.M.
	Other (income) and expense, net		(17		)	8			N.M.		27			12			125	%
	TOTAL OPERATING PROFIT		$	907		$	807		12.4	%	$	2,494		$	2,386		4.5	%
	N.M. - Not Meaningful
	(a)	Corporate & Other includes charges related to the health care spin-off and European strategic changes. See Notes 2 and 4.

Supplemental_Balance_Sheet_Dat

Supplemental Balance Sheet Data (Notes)	9 Months Ended
	Sep. 30, 2014
Statement of Financial Position [Abstract]	'
Additional Financial Information Disclosure	'
	Supplemental Balance Sheet Data
	The following schedule presents a summary of inventories by major class:
			September 30, 2014									December 31, 2013
			LIFO				Non-LIFO		Total			LIFO			Non-LIFO		Total
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials		$	146			$	334	$	480		$	143		$	319	$	462
	Work in process		176				110		286			189			97		286
	Finished goods		692				737		1,429			648			753		1,401
	Supplies and other		—				327		327			—			326		326
			1,014				1,508		2,522			980			1,495		2,475
	Excess of FIFO or weighted-average cost over LIFO cost		(241		)		—		(241		)	(242		)	—		(242		)
	Total		$	773			$	1,508	$	2,281		$	738		$	1,495	$	2,233
	We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time.
	The following schedule presents a summary of property, plant and equipment, net:
		September 30,				December 31,
		2014				2013
	Land	$	186			$	196
	Buildings	2,706				2,776
	Machinery and equipment	14,124				14,193
	Construction in progress	540				515
		17,556				17,680
	Less accumulated depreciation	(9,864		)		(9,732		)
	Total	$	7,692			$	7,948

Accounting_Policies_Accounting

Accounting Policies Accounting (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Accounting Policies
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form  10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.
	For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form  10-K for the year ended December 31, 2013. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. For 2014, we have completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter as the measurement date and have determined that goodwill is not impaired. The fair value for all reporting units was in excess of the book value.
	Highly Inflationary Accounting for Venezuelan Operations
	We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after-tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to this devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations.
	During March 2013, the Venezuelan government announced a complementary currency exchange system, SICAD. Participation in SICAD is controlled by the Venezuelan government. SICAD is intended to function as an auction system, allowing entities in specific sectors to bid for U.S. dollars to be used for specified import transactions. In February 2014, the president of Venezuela announced that another exchange system (referred to as SICAD 2) would be initiated. Initial exchanges under SICAD 2 began on March 24, 2014.
	We measure results in Venezuela at the rate in which we transact our business. Since March 2013, exchange transactions have taken place through letters of credit which resulted in an effective exchange rate of 6.3 bolivars per U.S. dollar and through approved transactions using the regulated currency exchange system, which were also at a 6.3 exchange rate. To date, we have not gained access to U.S. dollars in Venezuela through either SICAD or SICAD 2 auctions. Whether we will be able to access either SICAD system in the foreseeable future and what volume of currency exchange will transact through these alternative mechanisms is unclear. Accordingly, we continued to measure K-C Venezuela operations at the rate of 6.3 bolivars per U.S. dollar through September 30, 2014.
	Through September 30, 2014 we continued to manufacture products in Venezuela as well as import finished goods under approved letters of credit. However, recent government approvals to import raw materials under letters of credit are not at a level sufficient to sustain all of our manufacturing capabilities in country. Unless we are able to obtain further approvals to import raw materials through approved letters of credit or through the official government exchange system, we may be forced to curtail some or all of our local manufacturing until such approvals to import additional raw materials are forthcoming. We continue to seek approval for additional imports, as well as monitor the financial policies and practices of the Venezuelan government to assess the impact on our US GAAP accounting and reporting for our operations in that country.
	At September 30, 2014, K-C Venezuela had a bolivar-denominated net monetary asset position (primarily cash) of $435, and our net investment in K-C Venezuela was $572, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented less than 3 percent of consolidated net sales in 2014 and approximately 2 percent in 2013.
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance.  The standard is effective for public entities for annual and interim periods beginning after December 15, 2016.  Early adoption is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The effects of this standard on our financial position, results of operations and cash flows are not yet known.

Fair_Value_Information_Policy

Fair Value Information (Policy)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Level Measurements Policy	'
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Supplemental_Balance_Sheet_Dat1

Supplemental Balance Sheet Data (Policies)	9 Months Ended
	Sep. 30, 2014
Statement of Financial Position [Abstract]	'
Inventory Policy	'
	We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time.

European_Strategic_Changes_Tab

European Strategic Changes (Tables) (European Strategic Changes [Member])	9 Months Ended
	Sep. 30, 2014
European Strategic Changes [Member]	'
Restructuring Cost and Reserve	'
Schedule of Cash Charges Reconciled to Accrued Expenses	'
		2014			2013
	Accrued expenses - January 1	$	37		$	133
	Charges for workforce reductions and other exit costs	12			53
	Cash payments	(32		)	(132		)
	Currency and other	(2		)	(9		)
	Accrued expenses - September 30	$	15		$	45

Fair_Value_Information_Tables

Fair Value Information (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Assets And Liabilities Measured On A Recurring Basis	'
	Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements.
		September 30,				Fair Value Measurements
		2014				Level 1				Level 2				Level 3
	Assets
	Company-owned life insurance (“COLI”)	$	57			$	—			$	57			$	—
	Available-for-sale securities	24				24				—				—
	Derivatives	44				—				44				—
	Total	$	125			$	24			$	101			$	—
	Liabilities
	Derivatives	$	105			$	—			$	105			$	—
		December 31,				Fair Value Measurements
		2013				Level 1				Level 2				Level 3
	Assets
	COLI	$	55			$	—			$	55			$	—
	Available-for-sale securities	22				22				—				—
	Derivatives	62				—				62				—
	Total	$	139			$	22			$	117			$	—
	Liabilities
	Derivatives	$	49			$	—			$	49			$	—
Fair Value, by Balance Sheet Grouping	'
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value Hierarchy Level		Carrying Amount				Estimated Fair Value				Carrying Amount				Estimated Fair Value
				September 30, 2014								December 31, 2013
	Assets
	Cash and cash equivalents(a)	1		$	1,431			$	1,431			$	1,054			$	1,054
	Time deposits(b)	1		154				154				222				222
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(c)	2		213				213				63				63
	Long-term debt(d)	2		6,193				6,856				5,698				6,271
	Redeemable preferred securities of subsidiaries(e)	3		532				535				532				552
	Redeemable common securities of subsidiary(f)	3		46				46				46				46
	(a)	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(d)	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(e)	Redeemable preferred securities of subsidiaries are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates.
	(f)	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi1

Employee Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Components of net periodic benefit cost	'
	The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans:
		Pension Benefits						Other Benefits
		Three Months Ended September 30
		2014			2013			2014		2013
	Service cost	$	12		$	13		$	3	$	4
	Interest cost	70			63			9		9
	Expected return on plan assets	(83		)	(82		)	—		—
	Recognized net actuarial loss	25			28			—		2
	Curtailment	—			(1		)	—		—
	Other	1			2			—		—
	Net periodic benefit cost	$	25		$	23		$	12	$	15
		Pension Benefits						Other Benefits
		Nine Months Ended September 30
		2014			2013			2014		2013
	Service cost	$	36		$	40		$	9	$	12
	Interest cost	209			191			27		25
	Expected return on plan assets	(249		)	(246		)	—		—
	Recognized net actuarial loss	75			91			—		2
	Curtailment	—			(30		)	—		—
	Other	6			(1		)	—		—
	Net periodic benefit cost	$	77		$	45		$	36	$	39

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Average Common Shares Outstanding Basic and Diluted	'
		Three Months Ended		Nine Months Ended
		30-Sep		30-Sep
	(Millions of shares)	2014	2013	2014	2013
	Basic	373.3	382.8	376	384.9
	Dilutive effect of stock options	1.1	1.4	1.2	1.6
	Dilutive effect of restricted share and restricted share unit awards	1.5	1.6	1.6	1.5
	Diluted	375.9	385.8	378.8	388

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Components Of Stockholders' Equity	'
			Stockholders' Equity Attributable to
			The Corporation			Noncontrolling Interests
	Balance at December 31, 2013		$	4,856		$	284
	Net Income		1,609			25
	Other comprehensive income, net of tax
	Unrealized translation		(362		)	(3		)
	Employee postretirement benefits		72			—
	Other		19			—
	Stock-based awards exercised or vested		99			—
	Recognition of stock-based compensation		51			—
	Income tax benefits on stock-based compensation		30			—
	Shares repurchased		(1,162		)	—
	Dividends declared		(946		)	(26		)
	Other		(1		)	3
	Balance at September 30, 2014		$	4,265		$	283
Schedule of Accumulated Other Comprehensive Income (Loss)	'
			Unrealized Translation			Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2012		$	(26	)	$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income (loss) before reclassifications		(386		)	57				1				17
	(Income) loss reclassified from AOCI		—			28			(a)	(2		)	(a)	(8		)
	Net current period other comprehensive income (loss)		(386		)	85				(1		)		9
	Balance as of September 30, 2013		$	(412	)	$	(1,843	)		$	(54	)		$	(43	)
	Balance as of December 31, 2013		$	(525	)	$	(1,668	)		$	(15	)		$	(34	)
	Other comprehensive income (loss) before reclassifications		(362		)	(2		)		24				17
	(Income) loss reclassified from AOCI		—			49			(a)	1			(a)	2
	Net current period other comprehensive income (loss)		(362		)	47				25				19
	Balance as of September 30, 2014		$	(887	)	$	(1,621	)		$	10			$	(15	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 6).

Objectives_And_Strategies_For_1

Objectives And Strategies For Using Derivatives (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of All Derivative Instruments	'
		Assets				Liabilities
		September 30,		December 31,		September 30,		December 31,
		2014		2013		2014		2013
	Foreign currency exchange contracts	$	38	$	34	$	104	$	49
	Interest rate contracts	4		22		1		—
	Commodity price contracts	2		6		—		—
	Total	$	44	$	62	$	105	$	49

Description_Of_Business_Segmen1

Description Of Business Segments (Tables)	9 Months Ended
	Sep. 30, 2014
Description of Business Segments	'
Information Concerning Consolidated Operations by Business Segment	'
			Three Months Ended September 30								Nine Months Ended
											30-Sep
			2014			2013			Change		2014			2013			Change
	NET SALES
	Personal Care		$	2,475		$	2,383		3.9	%	$	7,299		$	7,170		1.8	%
	Consumer Tissue		1,697			1,626			4.4	%	5,024			4,969			1.1	%
	K-C Professional		873			843			3.6	%	2,531			2,477			2.2	%
	Health Care		392			403			-2.7	%	1,186			1,201			-1.2	%
	Corporate & Other		5			7			N.M.		23			30			N.M.
	TOTAL NET SALES		$	5,442		$	5,262		3.4	%	$	16,063		$	15,847		1.4	%
	OPERATING PROFIT
	Personal Care		$	483		$	427		13.1	%	$	1,393		$	1,300		7.2	%
	Consumer Tissue		285			233			22.3	%	782			713			9.7	%
	K-C Professional		165			155			6.5	%	455			459			-0.9	%
	Health Care		52			70			-25.7	%	187			168			11.3	%
	Corporate & Other(a)		(95		)	(70		)	N.M.		(296		)	(242		)	N.M.
	Other (income) and expense, net		(17		)	8			N.M.		27			12			125	%
	TOTAL OPERATING PROFIT		$	907		$	807		12.4	%	$	2,494		$	2,386		4.5	%
	N.M. - Not Meaningful
	(a)	Corporate & Other includes charges related to the health care spin-off and European strategic changes. See Notes 2 and 4.

Summary_of_Balance_Sheet_Data_

Summary of Balance Sheet Data (Tables)	9 Months Ended
	Sep. 30, 2014
Statement of Financial Position [Abstract]	'
Schedule of Inventory, Current	'
			September 30, 2014									December 31, 2013
			LIFO				Non-LIFO		Total			LIFO			Non-LIFO		Total
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials		$	146			$	334	$	480		$	143		$	319	$	462
	Work in process		176				110		286			189			97		286
	Finished goods		692				737		1,429			648			753		1,401
	Supplies and other		—				327		327			—			326		326
			1,014				1,508		2,522			980			1,495		2,475
	Excess of FIFO or weighted-average cost over LIFO cost		(241		)		—		(241		)	(242		)	—		(242		)
	Total		$	773			$	1,508	$	2,281		$	738		$	1,495	$	2,233
Property, Plant and Equipment	'
		September 30,				December 31,
		2014				2013
	Land	$	186			$	196
	Buildings	2,706				2,776
	Machinery and equipment	14,124				14,193
	Construction in progress	540				515
		17,556				17,680
	Less accumulated depreciation	(9,864		)		(9,732		)
	Total	$	7,692			$	7,948

Accounting_Policies_Narrative_

Accounting Policies Narrative (Details) (K-C Venezuela [Member], USD $)	3 Months Ended	9 Months Ended		12 Months Ended	33 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Feb. 01, 2013
K-C Venezuela [Member]	'	'	'	'	'
Central Bank System Rate	'	6.3	'	'	5.4
Charge for Devaluation Under Highly Inflationary Accounting (after tax)	$26	'	'	'	'
Charge for Devaluation Under Highly Inflationary Accounting	36	'	'	'	'
Bolivar Denominated Monetary Asset Net	'	435	'	'	'
Net Investment Foreign Operations	'	$572	'	'	'
Portion Of Consolidate Net Sales Earned By Affiliate Percent	'	3.00%	2.00%	3.00%	'

Spinoff_of_the_Health_Care_Bus

Spin-off of the Health Care Business Narrative (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Spinoff [Member]

Spinoff [Member]

Spinoff [Member]

Thailand Mill Closure [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Asset Impairments [Member]

Marketing, Research and General Expenses [Member]

Marketing, Research and General Expenses [Member]

Expected Charges [Member]

Spinoff [Member]

Thailand Mill Closure [Member]

Thailand Mill Closure [Member]

Thailand Mill Closure [Member]

Spinoff [Member]

Spinoff [Member]

Restructuring Cost and Reserve

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales

$5,442

$5,262

$16,063

$15,847

'

'

$1,700

'

'

'

'

'

'

'

Charges for workforce reductions and other exit costs

'

'

'

'

40

115

'

70

5

5

54

42

30

56

Restructuring Charges After Tax

'

'

'

'

$41

$94

'

$50

'

'

'

'

'

'

2014_Organization_Restructurin1

2014 Organization Restructuring 2014 Organization Restructuring Narrative (Details) (2014 Organization Restructuring [Member], USD $)	3 Months Ended
	Sep. 30, 2014
Cash Charges Percent of Total [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	$0.80
Minimum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	130,000,000
Restructuring and Related Cost, Expected Number of Positions Eliminated	1,100
Maximum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	160,000,000
Restructuring and Related Cost, Expected Number of Positions Eliminated	1,300
Before Tax [Member] | Minimum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	190,000,000
Before Tax [Member] | Maximum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	230,000,000
2014 Fourth Quarter Expected Charges [Member] | Minimum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	85,000,000
2014 Fourth Quarter Expected Charges [Member] | Maximum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	105,000,000
2014 Fourth Quarter Expected Charges [Member] | Before Tax [Member] | Minimum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	125,000,000
2014 Fourth Quarter Expected Charges [Member] | Before Tax [Member] | Maximum [Member]	'
Restructuring Cost and Reserve	'
Restructuring and Related Cost, Expected Cost	$150,000,000

European_Strategic_Changes_Nar

European Strategic Changes - Narrative (Details) (USD $)	3 Months Ended		9 Months Ended		23 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
European Strategic Changes [Member]	'	'	'	'	'
Restructuring Cost and Reserve	'	'	'	'	'
Charges for workforce reductions and other exit costs	$0	$0	$0	$0	$0
Restructuring Charges After Tax	0	0	12	52	0
European Strategic Changes [Member]	'	'	'	'	'
Restructuring Cost and Reserve	'	'	'	'	'
Restructuring Activities for Manufacturing Facilities	'	'	'	'	5
Cash charges [Member] | European Strategic Changes [Member]	'	'	'	'	'
Restructuring Cost and Reserve	'	'	'	'	'
Charges for workforce reductions and other exit costs	$12	$53	'	'	$0

European_Strategic_Changes_Rec

European Strategic Changes - Reconciliation to Accrued Expenses (Details) (European Strategic Changes [Member], USD $)	3 Months Ended		9 Months Ended		23 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Accrued Expense Roll Forward	'	'	'	'	'
Accrued expenses - January 1	'	'	$37	$133	'
Charges for workforce reductions and other exit costs	0	0	0	0	0
Cash payments	-32	-132	'	'	'
Currency and other	-2	-9	'	'	'
Accrued expenses - September 30	15	45	15	45	15
Cash charges [Member]	'	'	'	'	'
Accrued Expense Roll Forward	'	'	'	'	'
Charges for workforce reductions and other exit costs	$12	$53	'	'	$0

Fair_Value_Information_Narrati

Fair Value Information (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Transfers among fair value determination	$0	$0

Fair_Value_Information_Fair_Va

Fair Value Information (Fair Value Assets And Liabilities Measured On A Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	$57	$55
Available-for-sale securities	24	22
Derivatives	44	62
Total	125	139
Derivatives	105	49
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	0	0
Available-for-sale securities	24	22
Derivatives	0	0
Total	24	22
Derivatives	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	57	55
Available-for-sale securities	0	0
Derivatives	44	62
Total	101	117
Derivatives	105	49
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	0	0
Available-for-sale securities	0	0
Derivatives	0	0
Total	0	0
Derivatives	$0	$0

Fair_Value_Information_Fair_Va1

Fair Value Information (Fair Value Of Financial Instruments) (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash and cash equivalents(a)	$1,431	[1]	$1,054	[1]
Time deposits(b)	154	[2]	222	[2]
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Short-term debt(c)	213	[3]	63	[3]
Long-term debt(d)	6,193	[4]	5,698	[4]
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash and cash equivalents(a)	1,431	[1]	1,054	[1]
Time deposits(b)	154	[2]	222	[2]
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Short-term debt(c)	213	[3]	63	[3]
Long-term debt(d)	6,856	[4]	6,271	[4]
Preferred securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiaries(e)	532	[5]	532	[5]
Preferred securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiaries(e)	535	[5]	552	[5]
common securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiaries(e)	46	[6]	46	[6]
common securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiaries(e)	$46	[6]	$46	[6]
[1]	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
[2]	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
[3]	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
[4]	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
[5]	Redeemable preferred securities of subsidiaries are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest or dividend payment dates.
[6]	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi2

Employee Postretirement Benefits (Narrative) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'	'	'
Cash contribution to pension trusts	'	$180	$175
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year	$200	'	'

Employee_Postretirement_Benefi3

Employee Postretirement Benefits (Benefit Cost Information For Defined Benefit Plans And Other Postretirement Benefit Plans) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Defined Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans	'	'	'	'
Service cost	$12	$13	$36	$40
Interest cost	70	63	209	191
Expected return on plan assets	-83	-82	-249	-246
Recognized net actuarial loss	25	28	75	91
Curtailment	0	-1	0	-30
Other	1	2	6	-1
Net periodic benefit cost	25	23	77	45
Other Postretirement Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans	'	'	'	'
Service cost	3	4	9	12
Interest cost	9	9	27	25
Expected return on plan assets	0	0	0	0
Recognized net actuarial loss	0	2	0	2
Curtailment	0	0	0	0
Other	0	0	0	0
Net periodic benefit cost	$12	$15	$36	$39

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	Sep. 30, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
Earnings Per Share [Abstract]	'	'
Common shares outstanding	372.5	382.1

Earnings_Per_Share_Average_Com

Earnings Per Share (Average Common Shares Outstanding Basic And Diluted) (Details)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Basic	373.3	382.8	376	384.9
Dilutive effect of stock options	1.1	1.4	1.2	1.6
Dilutive effect of restricted share and restricted share unit awards	1.5	1.6	1.6	1.5
Diluted	375.9	385.8	378.8	388

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Equity [Abstract]	'
Repurchased shares	10.3
Stock Repurchased During Period, Value	$1,131

Stockholders_Equity_Components

Stockholders' Equity (Components Of Stockholders' Equity) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Balance at December 31, 2013	'	'	$5,140	'
Net Income	582	565	1,658	1,663
Unrealized currency translation adjustments	-529	204	-366	-387
Employee postretirement benefits	46	-5	72	84
Other	30	-19	19	9
Balance at September 30, 2014	4,548	'	4,548	'
Parent [Member]	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Balance at December 31, 2013	'	'	4,856	'
Net Income	'	'	1,609	'
Unrealized currency translation adjustments	'	'	-362	-386
Employee postretirement benefits	'	'	72	'
Other	'	'	19	9
Stock-based awards exercised or vested	'	'	99	'
Recognition of stock-based compensation	'	'	51	'
Income tax benefits on stock-based compensation	'	'	30	'
Shares repurchased	'	'	-1,162	'
Dividends declared	'	'	-946	'
Other	'	'	-1	'
Balance at September 30, 2014	4,265	'	4,265	'
Noncontrolling Interests [Member]	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Balance at December 31, 2013	'	'	284	'
Net Income	'	'	25	'
Unrealized currency translation adjustments	'	'	-3	'
Employee postretirement benefits	'	'	0	'
Other	'	'	0	'
Stock-based awards exercised or vested	'	'	0	'
Recognition of stock-based compensation	'	'	0	'
Income tax benefits on stock-based compensation	'	'	0	'
Shares repurchased	'	'	0	'
Dividends declared	'	'	-26	'
Other	'	'	3	'
Balance at September 30, 2014	$283	'	$283	'

Stockholders_Equity_Components1

Stockholders' Equity (Components of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013
Unrealized translation - Beginning balance	'	'	($525)		($26)
Cash flow hedge and other - Beginning balance	'	'	-34		-52
Other comprehensive income/(loss) before reclassifications	'	'	-362		-386
(Income)/loss reclassified from AOCI	'	'	0		0
Other comprehensive income/(loss) before reclassifications	'	'	17		17
Income/loss reclassified from AOCI	'	'	2		-8
Unrealized currency translation adjustments	-529	204	-366		-387
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	-46	5	-72		-84
Unrealized translation - Ending balance	-887	-412	-887		-412
Cash flow hedge and other - Ending balance	-15	-43	-15		-43
Other	30	-19	19		9
Pension Plans, Defined Benefit [Member]	'	'	'		'
Defined benefit and other postretirement benefit plans - Beginning balance	'	'	-1,668		-1,928
Other comprehensive income/(loss) before reclassifications	'	'	-2		57
(Income)/loss reclassified from AOCI	'	'	49	[1]	28	[1]
Defined benefit and other postretirement benefit plans - Ending balance	-1,621	-1,843	-1,621		-1,843
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'		'
Defined benefit and other postretirement benefit plans - Beginning balance	'	'	-15		-53
Other comprehensive income/(loss) before reclassifications	'	'	24		1
(Income)/loss reclassified from AOCI	'	'	1	[1]	-2	[1]
Defined benefit and other postretirement benefit plans - Ending balance	10	-54	10		-54
Parent [Member]	'	'	'		'
Unrealized currency translation adjustments	'	'	-362		-386
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	-72		'
Other	'	'	19		9
Parent [Member] | Pension Plans, Defined Benefit [Member]	'	'	'		'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	-47		-85
Parent [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'		'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	($25)		$1
[1]	(a)Included in computation of net periodic pension and postretirement benefits costs (see Note 6).

Objectives_And_Strategies_For_2

Objectives And Strategies For Using Derivatives (Narratives) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Fair Value Hedge Ineffectiveness is Immaterial Assertion	'	'	'Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2014 and 2013	'
Gain from Hedged Firm Commitment Not Qualifying as Fair Value Hedge	'	'	$0	$0
Cash Flow Hedge Ineffectiveness is Immaterial	'	'	'Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2014 and 2013	'
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net	'	'	0	0
Not Designated as Hedging Instrument [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Notional Amount	2,400,000,000	'	2,400,000,000	'
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	-130,000,000	77,000,000	-77,000,000	65,000,000
Cash Flow Hedging [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Maturity Date	'	'	1-Jul-17	'
Net Investment Hedging [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Notional Amount	74,000,000	'	74,000,000	'
Interest Rate Swap [Member] | Fair Value Hedging [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Notional Amount	250,000,000	'	250,000,000	'
Interest Rate Swap [Member] | Cash Flow Hedging [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Notional Amount	200,000,000	'	200,000,000	'
Foreign currency exchange contracts | Cash Flow Hedging [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Notional Amount	$899,000,000	'	$899,000,000	'

Objectives_And_Strategies_For_3

Objectives And Strategies For Using Derivatives Summary of total and undesignated fair values of derivative instruments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Derivative	'	'
Assets	$44	$62
Liabilities	105	49
Foreign currency exchange contracts	'	'
Derivative	'	'
Assets	38	34
Liabilities	104	49
Interest rate contracts	'	'
Derivative	'	'
Assets	4	22
Liabilities	1	0
Commodity price contracts	'	'
Derivative	'	'
Assets	2	6
Liabilities	$0	$0

Description_Of_Business_Segmen2

Description Of Business Segments (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Net Sales	$5,442		$5,262		$16,063		$15,847
Percent change	12.39%		'		125.00%		'
Total Operating Profit	907		807		2,494		2,386
Other (income) and expense, net	-17		8		27		12
Net Sales [Member]	'		'		'		'
Percent change	3.42%		'		1.36%		'
Operating Profit [Member]	'		'		'		'
Percent change	'		'		4.53%		'
Personal Care [Member]	'		'		'		'
Net Sales	2,475		2,383		7,299		7,170
Total Operating Profit	483		427		1,393		1,300
Personal Care [Member] | Net Sales [Member]	'		'		'		'
Percent change	3.86%		'		1.80%		'
Personal Care [Member] | Operating Profit [Member]	'		'		'		'
Percent change	13.11%		'		7.15%		'
Consumer Tissue [Member]	'		'		'		'
Net Sales	1,697		1,626		5,024		4,969
Total Operating Profit	285		233		782		713
Consumer Tissue [Member] | Net Sales [Member]	'		'		'		'
Percent change	4.37%		'		1.11%		'
Consumer Tissue [Member] | Operating Profit [Member]	'		'		'		'
Percent change	22.32%		'		9.68%		'
K-C Professional	'		'		'		'
Net Sales	873		843		2,531		2,477
Total Operating Profit	165		155		455		459
K-C Professional | Net Sales [Member]	'		'		'		'
Percent change	3.56%		'		2.18%		'
K-C Professional | Operating Profit [Member]	'		'		'		'
Percent change	6.45%		'		-0.87%		'
Health Care [Member]	'		'		'		'
Net Sales	392		403		1,186		1,201
Total Operating Profit	52		70		187		168
Health Care [Member] | Net Sales [Member]	'		'		'		'
Percent change	-2.73%		'		-1.25%		'
Health Care [Member] | Operating Profit [Member]	'		'		'		'
Percent change	-25.71%		'		11.31%		'
Corporate and Other [Member]	'		'		'		'
Net Sales	5		7		23		30
Total Operating Profit	($95)	[1]	($70)	[1]	($296)	[1]	($242)	[1]
[1]	Corporate & Other includes charges related to the health care spin-off and European strategic changes. See Notes 2 and 4.

Supplemental_Balance_Sheet_Dat2

Supplemental Balance Sheet Data - Inventory (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Raw materials	$480	$462
Work in process	286	286
Finished goods	1,429	1,401
Supplies and other	327	326
Inventory, Gross	2,522	2,475
Excess of FIFO or weighted-average cost over LIFO cost	-241	-242
Total	2,281	2,233
LIFO [Member]	'	'
Raw materials	146	143
Work in process	176	189
Finished goods	692	648
Supplies and other	0	0
Inventory, Gross	1,014	980
Excess of FIFO or weighted-average cost over LIFO cost	-241	-242
Total	773	738
Non-LIFO [Member]	'	'
Raw materials	334	319
Work in process	110	97
Finished goods	737	753
Supplies and other	327	326
Inventory, Gross	1,508	1,495
Excess of FIFO or weighted-average cost over LIFO cost	0	0
Total	$1,508	$1,495

Supplemental_Balance_Sheet_Dat3

Supplemental Balance Sheet Data - Property Plant and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Land	$186	$196
Buildings	2,706	2,776
Machinery and equipment	14,124	14,193
Construction in progress	540	515
Property, Plant and Equipment, Gross	17,556	17,680
Less accumulated depreciation	-9,864	-9,732
Total	$7,692	$7,948